Drug Trial Radar · NCT07297654
First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 27, 2026
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- National Cancer Center, KoreaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Asan Medical Center; Seoul National University Hospital; Seoul National University Bundang Hospital; Samsung Medical Center; Hanyang University Guri Hospital
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.
Conditions
- Advanced Hepatocellular Carcinoma
Interventions
LenvatinibDrug
Lenvatinib will be administered orally at a dose of 8 mg once daily at the same time each day, with or without food (regardless of body weight). For participants with a baseline body weight ≥60 kg who tolerate lenvatinib at 8 mg once daily (i.e., experiencing only Grade 1 or lower adverse events) and have maintained this dose for at least 2 weeks, the daily dose of lenvatinib may be increased to 12 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center
Goyang-si, South Korea · Recruiting
Hanyang University Guri Hospital
Guri-si, South Korea · Not yet recruiting
Seoul National University Bundang Hospital
Seongnam-si, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.